Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection

Documenti analoghi

• Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects
  di: Zhou, Xiao-Jian, et al.
  Pubblicazione: (2011)
• First-in-Human Study of the Pharmacokinetics and Antiviral Activity of IDX375, a Novel Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
  di: de Bruijne, J., et al.
  Pubblicazione: (2012)
• Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects
  di: Zhou, Xiao-Jian, et al.
  Pubblicazione: (2009)
• Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
  di: Feng, Joy Y., et al.
  Pubblicazione: (2016)
• IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study
  di: Elfiky, Abdo A., et al.
  Pubblicazione: (2016)